BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37657939)

  • 1. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
    Alam JJ; Maruff P; Doctrow SR; Chu HM; Conway J; Gomperts SN; Teunissen C
    Neurology; 2023 Oct; 101(17):e1708-e1717. PubMed ID: 37657939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
    Prins ND; de Haan W; Gardner A; Blackburn K; Chu HM; Galvin JE; Alam JJ
    J Prev Alzheimers Dis; 2024; 11(3):549-557. PubMed ID: 38706271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.
    Jiang Y; Alam JJ; Gomperts SN; Maruff P; Lemstra AW; Germann UA; Stavrides PH; Darji S; Malampati S; Peddy J; Bleiwas C; Pawlik M; Pensalfini A; Yang DS; Subbanna S; Basavarajappa BS; Smiley JF; Gardner A; Blackburn K; Chu HM; Prins ND; Teunissen CE; Harrison JE; Scheltens P; Nixon RA
    Nat Commun; 2022 Sep; 13(1):5308. PubMed ID: 36130946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
    Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
    Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
    Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
    JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease.
    Thomas AJ; Hamilton CA; Heslegrave A; Barker S; Durcan R; Lawley S; Barnett N; Lett D; Firbank M; Roberts G; Taylor JP; Donaghy PC; Zetterberg H; O'Brien J
    Mov Disord; 2022 Jul; 37(7):1495-1504. PubMed ID: 35318733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.
    Querfurth HW; Allam GJ; Geffroy MA; Schiff HB; Kaplan RF
    Dement Geriatr Cogn Disord; 2000; 11(6):314-21. PubMed ID: 11044776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease.
    Sim J; Li H; Hameed S; Ting SKS
    JAMA Neurol; 2022 Jul; 79(7):702-709. PubMed ID: 35604656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
    Lemstra AW; de Beer MH; Teunissen CE; Schreuder C; Scheltens P; van der Flier WM; Sikkes SA
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):113-118. PubMed ID: 27794030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
    van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW
    Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia.
    Jellinger KA
    J Neural Transm (Vienna); 2023 Jul; 130(7):891-904. PubMed ID: 37306790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease.
    Malek-Ahmadi M; Beach TG; Zamrini E; Adler CH; Sabbagh MN; Shill HA; Jacobson SA; Belden CM; Caselli RJ; Woodruff BK; Rapscak SZ; Ahern GL; Shi J; Caviness JN; Driver-Dunckley E; Mehta SH; Shprecher DR; Spann BM; Tariot P; Davis KJ; Long KE; Nicholson LR; Intorcia A; Glass MJ; Walker JE; Callan M; Curry J; Cutler B; Oliver J; Arce R; Walker DG; Lue LF; Serrano GE; Sue LI; Chen K; Reiman EM
    PLoS One; 2019; 14(6):e0217566. PubMed ID: 31237877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
    Kaufer DI
    Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():32-9. PubMed ID: 14676467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.
    Llibre-Guerra JJ; Li Y; Schindler SE; Gordon BA; Fagan AM; Morris JC; Benzinger TLS; Hassenstab J; Wang G; Allegri R; Berman SB; Chhatwal J; Farlow MR; Holtzman DM; Jucker M; Levin J; Noble JM; Salloway S; Schofield P; Karch C; Fox NC; Xiong C; Bateman RJ; McDade E
    JAMA Netw Open; 2019 Dec; 2(12):e1917126. PubMed ID: 31825500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia.
    Thomas AJ; Mahin-Babaei F; Saidi M; Lett D; Taylor JP; Walker L; Attems J
    Alzheimers Res Ther; 2018 Mar; 10(1):27. PubMed ID: 29490691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.